medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2010, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2010; 8 (3)

Comparative study between 5-fluorouracil 0.5% in liposome encapsulated and 5-fluorouracil 5%, cream in actinic keratoses treatment

Domínguez SL, Hojyo MT, Eljure N, Ranone VA, Garibay VM, Fortuño CV

Language: Spanish
References: 40
Page: 173-183
PDF size: 391.53 Kb.


ABSTRACT

Background: Actinic keratoses are premalignant lesions related to chronic sun damage. One of the most effective treatments is the 5% 5-fluoruracil (5-FU) cream.
Objectives: A comparative study in actinic keratoses to evaluate 0.5% liposomal 5-fluorouracil once or twice a day, or 5% 5-FU cream once a day.
Material and methods: Patients ‹35 year-old with clinical diagnosis of actinic keratoses confirmed by biopsy were assigned to one of tree treatment groups: Group A, 0.5% liposomal 5-fluorouracil at morning and a placebo at night; Group B, 0.5% liposomal 5-fluorouracil at morning and night; and Group C, 5-fluorouracil 5% cream at morning and night for 4 weeks. Patients were evaluated weekly for 4 weeks and at the 7th week.
Results: 120 patients completed the study: 40 in Group A, 38 in Group B and 42 in Group C. There were no statistical differences in demographic characteristics nor skin type among the 3 groups. Lesion disappearance at 7 weeks was observed in 27 out of 40 (67.50%) in Group A; 24 out of 38 (63.15%) in Group B; and 33 out of 42 (78.50%) in Group C. No severe adverse events were registered.
Conclusions: Results showed a trend that 0.5% liposomal 5-fluorouracil once a day is similar to 5-fluorouracil 5% cream twice a day in the treatment of actinic queratoses with clinical and histological remission of the lesion.


REFERENCES

  1. Moy RL. “Clinical presentation of actinic keratoses and squamous cell carcinoma”. J Am Acad Dermatol 2000; 42 (1 Pt 2): 8-10.

  2. Berman B, Bienstock L, Kuritzky L, Mayeaux EJ, Jr, Tyring SK. “Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel”. J Fam Pract 2006; 55 (5, supl. 8).

  3. Schwartz RA. “The actinic keratosis. A perspective and update”. Dermatol Surg 1997; 23 (11): 1009-1019.

  4. Kuflik AS, Schwartz RA. “Actinic keratosis and squamous cell carcinoma”. Am Fam Physician 1994; 49 (4): 817-820.

  5. Yu RC, Pryce DW, Macfarlane AW, Stewart TW. “A histopathological study of 643 cutaneous horns”. Br J Dermatol 1991; 124 (5): 449-452.

  6. Schosser RH, Hodge SJ, Gaba CR, Owen LG. “Cutaneous horns: A histopathologic study”. South Med J 1979; 72 (9): 1129-1131.

  7. Hemminki K, Zhang H, Czene K. “Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol 2003; 139 (7): 885-889.

  8. Diepgen TL, Mahler V. “The epidemiology of skin cancer”. Br J Dermatol 2002; 146 (supl. 61): 1-6.

  9. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL y cols. “Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years”. JAMA 2005; 294 (6): 681-690.

  10. European Dermatology Forum. “Guidelines for the management of actinic keratoses” En: http://www.euroderm.org de content de guidelines_ keratoses.htm, 2005, 15 de enero de 2009. Internet Communication.

  11. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. “The development of actinic keratosis into invasive squamous cell carcinoma: Evidence and evolving classification schemes.” Clin Dermatol 2004; 22 (3): 189-196.

  12. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. “Prevalence of solar damage and actinic keratosis in a Merseyside population”. Br J Dermatol 2000; 142 (6): 1154-1159.

  13. Zagula-Mally ZW, Rosenberg EW, Kashgarian M. “Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling”. Cancer 1974; 34 (2): 345-349.

  14. Frost C, Williams G, Green A. “High incidence and regression rates of solar keratoses in a Queensland community”. J Invest Dermatol 2000; 115 (2): 273-277.

  15. Green A, Beardmore G, Hart V, Leslie D, Marks R, Staines D. “Skin cancer in a Queensland population”. J Am Acad Dermatol 1988; 19 (6): 1045-1052.

  16. Helfand M, Gorman AK, Mahon S. “Actinic Keratoses Final Report. U.S. Department of Health and Human Services”. http://www.cms.hhs.gov de coverage de download de 8b3-t3.pdf, 2005, 15 de enero de 2009, Internet Communication

  17. Lookingbill DP, Lookingbill GL, Leppard B. “Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program”. J Am Acad Dermatol 1995; 32 (4): 653-658.

  18. Lehmann AR, Bridges BA. “Sunlight-induced cancer: Some new aspects and implications of the xeroderma pigmentosum model”. Br J Dermatol 1990; 122 (supl. 35): 115-119.

  19. Lambert WC, Kuo HR, Lambert MW. “Xeroderma pigmentosum”. Dermatol Clin 1995; 13 (1): 169-209.

  20. Luande J, Henschke CI, Mohammed N. “The Tanzanian human albino skin. Natural history”. Cancer 1985; 55 (8): 1823-1828.

  21. Cooper KD, Fox P, Neises G, Katz SI. “Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of Langerhans cell-dependent function is followed by the appearance of T6- Dr+ cells that enhance epidermal alloantigen presentation”. J Immunol 1985; 134 (1): 129-137.

  22. Granstein RD, Askari M, Whitaker D, Murphy GF. “Epidermal cells in activation of suppressor lymphocytes: further characterization”. J Immunol 1987 Jun; 138 (12): 4055-4062.

  23. Levine AJ, Momand J, Finlay CA. “The p53 tumour suppressor gene”. Nature 1991; 351 (6326): 453-456.

  24. Vogelstein B, Kinzler KW. “p53 function and dysfunction”. Cell 1992; 70 (4): 523-526.

  25. Lane DP. “Cancer. p53, guardian of the genome”. Nature 1992; 358 (6381): 15-16.

  26. Suchniak JM, Baer S, Goldberg LH. “High rate of malignant transformation in hyperkeratotic actinic keratoses”. J Am Acad Dermatol 1997; 37 (3 Pt 1): 392-394.

  27. Fu W, Cockerell CJ. “The actinic (solar) keratosis: a 21st-century perspective”. Arch Dermatol 2003; 139 (1): 66-70.

  28. Dinehart SM. “The treatment of actinic keratoses”. J Am Acad Dermatol 200; 42 (1 Pt 2): S25-S28.

  29. Duncan KO, Geisse JK, Leffell DJ. “Epithelial Precancerous Lesions, Actinic Keratoses”. En: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, (eds.) Fitzpatrick Dermatology in General Medicine. 7a ed, McGraw Hill; 2008, 1007-1015.

  30. Chiarello SE. “Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: An update and comparison”. Dermatol Surg 2000; 26 (8): 728-732.

  31. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. “Imiquimod in basal cell carcinoma: How does it work?” Br J Dermatol 2003; 149 (supl. 66): 57-58.

  32. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C y cols. “A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses”. Arch Dermatol 2002; 138 (11): 1498-1502.

  33. Stockfleth E, Christophers E, Benninghoff B, Sterry W. “Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study”. Arch Dermatol 2004; 140 (12): 1542.

  34. Salasche SJ, Levine N, Morrison L. “Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial”. J Am Acad Dermatol 2002; 47 (4): 571-577.

  35. Harmon CB. “Dermabrasion”. Dermatol Clin 2001; 19 (3): 439-442, viii.

  36. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J y cols. “Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehiclecontrolled trials”. J Am Acad Dermatol 2004; 50 (5): 714-721.

  37. Gupta AK, Davey V, Mcphail H. “Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies”. J Cutan Med Surg 2005; 9 (5): 209-214.

  38. Falagas ME, Angelousi AG, Peppas G. “Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials”. J Am Acad Dermatol 2006; 55 (3): 537-538.

  39. Hadley G, Derry S, Moore RA. “Imiquimod for actinic keratosis: systematic review and meta-analysis”. J Invest Dermatol 2006; 126 (6): 1251- 1255.

  40. Gupta AK, Glover AM. “Fluorouracil Formulations for the Treatment of Actinic Keratosis”. Am J Cancer 2005; 4 (2): 115-126.




2020     |     www.medigraphic.com